# Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

Study · id `cardio:ct-nct03212365` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03212365](<https://clinicaltrials.gov/study/NCT03212365>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03212365

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.

## Technical summary

Registry record NCT03212365. Randomized; double masking; primary purpose other. Start 2017-07-03 (actual); primary completion 2019-06-02 (actual). Results posted on 2020-09-16.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose other
- Phase: Phase 2
- Enrolled: 295 participants (enrolled count; ClinicalTrials.gov record NCT03212365, source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)
- Started: 2017-07-03 (actual) (ClinicalTrials.gov record NCT03212365, source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)
- Primary completion: 2019-06-02 (actual) (ClinicalTrials.gov record NCT03212365, source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)
- Completion: 2019-10-01 (actual) (ClinicalTrials.gov record NCT03212365, source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)
- Results first posted: 2020-09-16 (ClinicalTrials.gov record NCT03212365, source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03212365, source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03212365-2020-09-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
- Condition: Venous Thromboembolism
- Condition: Deep Venous Thrombosis
- Condition: Pulmonary Embolus
- Condition: Reconstructive Surgery
- Intervention (Drug): Fixed dose
- Intervention (Drug): Variable dose
- Lead sponsor: University of Utah
- Lead sponsor class: OTHER
- Collaborator: Stanford University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: University of Utah (`cardio:org-university-of-utah`)
- Registry lists this organization as a collaborator: Stanford University (`cardio:org-stanford-university`)

## Provenance

Content hash: 0534dc8f167fa35636b08a4de39d8d510aea45176a9649964f39edefb5e1e6e4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
